|
FDA Advisers Recommend Approval of Gilead's Quad, Truvada HIV Drugs
Gilead Sciences’ Quad HIV treatment and its HIV-prevention drug Truvada both have acceptable benefit-risk profiles and should be approved with robust postmarket strings attached, FDA reviewers say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives